Skip to main content
. Author manuscript; available in PMC: 2015 Aug 1.
Published in final edited form as: Invest New Drugs. 2014 Apr 10;32(4):604–617. doi: 10.1007/s10637-014-0084-7

Fig. 2.

Fig. 2

(a) Ability to induce cell cycle modulation was assessed by flow cytometry at 24h revealing that WA treatment results in dose-dependent G2/M cell cycle arrest. Maximum arrest was observed at 2μM and 1.5μM for U251TMZ and U87TMZ cells, respectively. (b) Histograms demonstrate cell cycle distribution for U251TMZ and U87TMZ cells at concentrations up to those yielding maximal arrest. (c) Arrest in G2/M phase was molecularly confirmed by immunoblotting for cyclin B1 at 24-48h. Highest levels of cyclin B1 were observed at 2.5μM and 1μM WA for U251TMZ and U87TMZ cells, respectively, confirming flow cytometry findings.